Safety of Matrix-M-adjuvanted COVID-19, seasonal influenza, combination influenza-COVID-19, and malaria vaccines: a review of the evidence - PubMed
7 hours ago
- #Matrix-M adjuvant
- #clinical trials
- #vaccine safety
- Matrix-M adjuvant induces potent and durable immunity through memory B-cells and broad T-cell immunity.
- Two authorized Matrix-M-adjuvanted vaccines are NUVAXOVID (COVID-19) and R21/Matrix-M (malaria), administered to >10 million people.
- Review includes safety data from 66 clinical trials and post-marketing studies of Matrix-M-adjuvanted vaccines for COVID-19, influenza, combination COVID-19-influenza, and malaria.
- 64,101 participants received ≥1 Matrix-M-adjuvanted vaccine dose (143,170 doses), with vaccines well-tolerated across diverse populations.
- Matrix-M-adjuvanted vaccines show favorable reactogenicity profiles compared to licensed vaccines, with lower reactogenicity rates post-NUVAXOVID vs. mRNA COVID-19 vaccines.
- Ongoing research aims to better understand Matrix-M mechanisms, improve technology, and identify new applications.